[New oral anticoagulants in the treatment of venous thromboembolic disease].
摘要:
Rivaroxaban is a direct inhibitor of activated factor X, and dabigatran is a direct inhibitor of thrombin. These new oral anticoagulants have demonstrated to be effective and safe in clinical trials on the treatment of venous thromboembolic disease (deep vein thrombosis and pulmonary thromboembolism).
收起
展开
DOI:
10.1016/j.semerg.2012.10.007
被引量:
年份:
1970


通过 文献互助 平台发起求助,成功后即可免费获取论文全文。
求助方法1:
知识发现用户
每天可免费求助50篇
求助方法1:
关注微信公众号
每天可免费求助2篇
求助方法2:
完成求助需要支付5财富值
您目前有 1000 财富值
相似文献(174)
参考文献(0)
引证文献(0)
来源期刊
影响因子:暂无数据
JCR分区: 暂无
中科院分区:暂无